Další formáty:
BibTeX
LaTeX
RIS
@article{2242241,
author = {Eid, Michal and Jelínková, Martina and Šána, Jiří and Slabý, Ondřej},
article_location = {Amsterdam},
article_number = {December 2022},
doi = {http://dx.doi.org/10.1016/j.cpccr.2022.100207},
keywords = {BRAF; Case report; Colorectal cancer; Comprehensive genomic profiling; KRAS},
language = {eng},
issn = {2666-6219},
journal = {Current Problems in Cancer: Case Reports},
title = {Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review},
url = {https://www.scopus.com/record/display.uri?eid=2-s2.0-85143854833&origin=resultslist&sort=plf-f},
volume = {8},
year = {2022}
}
TY - JOUR
ID - 2242241
AU - Eid, Michal - Jelínková, Martina - Šána, Jiří - Slabý, Ondřej
PY - 2022
TI - Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review
JF - Current Problems in Cancer: Case Reports
VL - 8
IS - December 2022
SP - 1-4
EP - 1-4
PB - Elsevier
SN - 26666219
KW - BRAF
KW - Case report
KW - Colorectal cancer
KW - Comprehensive genomic profiling
KW - KRAS
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85143854833&origin=resultslist&sort=plf-f
N2 - The presence of activating somatic mutations in the KRAS and NRAS oncogenes is a negative predictor of treatment with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody in colorectal cancer. The BRAF oncogene also plays an important role in carcinogenesis, and, in colorectal cancer, is associated with an unfavorable prognosis. Mutations in RAS and BRAF are usually considered mutually exclusive. Concomitant mutations present in these oncogenes are rare. However, according to recent analyzes, the incidence of concomitant RAS and BRAF mutations in colorectal cancer may be higher than it is currently expected. In the presented case report of a 44-year-old woman treated for metastatic rectal cancer with concomitant KRAS and BRAF mutations in primary tumor and wild-type KRAS status in metastases, we demonstrated improved survival outcome and quality of life after treatment with BRAF inhibitor encorafenib and the anti-EGFR monoclonal antibody cetuximab.
ER -
EID, Michal, Martina JELÍNKOVÁ, Jiří ŠÁNA a Ondřej SLABÝ. Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review. \textit{Current Problems in Cancer: Case Reports}. Amsterdam: Elsevier, 2022, roč.~8, December 2022, s.~1-4. ISSN~2666-6219. Dostupné z: https://dx.doi.org/10.1016/j.cpccr.2022.100207.
|
